磷酸芦可替尼Ruxolitinib 20mg

Indicated for the treatment of adult patients with disease-related splenomegaly, or for relieving symptoms in adult patients with primary myelofibrosis (PMF, also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), as well as graft-versus-host disease.

A complete blood count, including a differential leukocyte count, must be performed prior to the initiation of treatment with this product. Administer orally, with or without food, as directed by the physician. Myelofibrosis Platelet count > 200×10⁹/L: 20 mg orally, twice daily. Platelet count 100×10⁹/L to 200×10⁹/L: 15 mg orally, twice daily. Platelet count 50×10⁹/L to < 100×10⁹/L: 5 mg orally, twice daily. Monitor blood tests every 2 to 4 weeks until levels stabilize, and observe any symptoms during medication to adjust the dose appropriately. Polycythemia Vera The initial dose of acalabrutinib is 10 mg orally, twice daily. Acute Graft-versus-Host Disease The initial dose of acalabrutinib is 5 mg orally, twice daily. Chronic Graft-versus-Host Disease The initial dose of acalabrutinib is 10 mg orally, twice daily.

Thrombocytopenia, anemia, and neutropenia may occur. Resolve bacterial infections before initiating treatment with acalabrutinib. Symptoms may worsen after interruption or discontinuation of the medication. May increase the risk of skin cancer. Exercise caution when administering to children.

Decreased platelet count and anemia. Infections and edema.

56 tablets per bottle.

Store at room temperature (20–25℃). Keep out of the reach of children.